Search

Enter the Dragons’ Den: Bob Gokani

I have often daydreamed about inventing a successful new product and then going on to pitch for investment on Dragons’ Den, with the TV show’s seasoned entrepreneurs all competing with each other to invest in my company. My imagined fantasy...

Enter the Dragons’ Den: Bob Gokani

I have often daydreamed about inventing a successful new product and then going on to pitch for investment on Dragons’ Den, with the TV show’s seasoned entrepreneurs all competing with each other to invest in my company. My imagined fantasy...

Intraocular lens choice in patients who have undergone previous corneal refractive surgery

Patients who underwent vision correction in their 20s to 40s are now entering their 50s and 60s, the typical starting age for cataract development [1]. Consequently, ophthalmologists are increasingly encountering patients whose corneal profiles have been surgically altered, requiring advanced...

Childhood glaucoma

When a child is given a diagnosis of glaucoma, the impact upon that child and their family is enormous; equivalent to the diagnosis of a cancer [14]. This previously published article (2019) outlines the knowledge, techniques and approaches that offer...

Newer generation IOL platforms designed for high-quality visual performance after cataract surgery

Expanding intraocular lens (IOL) capabilities provide broadening options, ranging from next-generation monofocal IOLs for basic cataract surgery, to specialised premium IOLs for lens-based presbyopia correction and astigmatism correction at the time of cataract surgery. Rod McNeil considers several newer alternative...

What’s new in wet AMD papers?

Paper presentations on neovascular (‘wet’) age-related macular degeneration (AMD) from the 16th European Society of Retina Specialists Congress, Copenhagen, September 2016, outline recent research directions evaluating the impact of vision loss on key health domains, patient preferences in the process...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...

Blinking blepharitis has a lot to answer for…

Never ignore the small things’…someone once said. There is no doubt blepharitis is one of the most common eye conditions encountered daily, but with the typical pressures of a busy outpatient department, the management of more obvious, sight-threatening conditions necessarily...

COVID-19: Pete’s Bogus Journey

The author shares his personal experience of contracting coronavirus. I managed to body swerve COVID-19 for nine months. The Pfizer vaccine was being rolled out in my trust. I had my first inoculation booked in three weeks. I had survived...

Strabismus and ocular motility, demystified

I am a former orthoptist, now trained in medicine and working as a foundation doctor. In my previous work, I was frequently approached by ophthalmology trainees eager for guidance with strabismus and ocular motility. Drawing on my clinical experience, I...